
GoodRx Announces Exclusive Low Cash Price for QSYMIA®, Making Weight Management More Accessible
GoodRx (Nasdaq: GDRX), the leading U.S. prescription savings platform, has announced that QSYMIA® (phentermine and topiramate extended-release capsules CIV) will be available at an exclusive low cash price in over 70,000 retail pharmacy locations nationwide. This initiative not only enhances GoodRx’s offerings in weight management solutions but also expands its portfolio of significant savings on brand-name medications, making obesity treatment more accessible and affordable for millions.
“Obesity medications can transform lives for many Americans, yet affordability and accessibility remain significant hurdles for consumers,” said Dorothy Gemmell, Chief Commercial Officer at GoodRx.
The CDC reports that more than 40% of U.S. adults are affected by obesity, which can lead to serious health risks such as type 2 diabetes, hypertension, and heart disease. With rising demand for weight-loss medications, many consumers face challenges in accessing these treatments due to high costs and inadequate insurance coverage. By providing better access to QSYMIA, GoodRx and Vivus are assisting individuals struggling with weight management to find more affordable treatment options.
Anyone with a valid prescription can now purchase a 30-day supply of QSYMIA through GoodRx for the exclusive cash price of $149, regardless of their insurance status. QSYMIA helps patients control hunger and curb cravings throughout the day, and when combined with a healthy diet and exercise, it has been shown to aid in weight loss and maintenance. Many patients prefer oral medications to injectables, as the convenience of taking a daily pill can improve adherence to treatment plans.
Through its partnership with VIVUS, GoodRx is committed to improving access to critical medications. “We are focused on expanding the availability of essential treatments that consumers depend on,” said John Amos, CEO of VIVUS. “Partnering with GoodRx allows us to provide an affordable option for those with prescriptions for QSYMIA, offering an unprecedented value compared to other therapies.”
GoodRx collaborates with nearly 150 brands across the pharmaceutical and healthcare industries to connect patients with savings and support programs. Recently, GoodRx also partnered with Pfizer to offer menopause hormone therapies at reduced prices and launched an affordability program with ARS Pharmaceuticals for neffy.
About GoodRx
GoodRx is the leading prescription savings platform in the U.S., trusted by over 25 million consumers and 750,000 healthcare professionals annually. The platform offers access to significant savings on both generic and brand-name medications across more than 70,000 pharmacies nationwide. Since its inception in 2011, GoodRx has helped consumers save over $75 billion on prescription costs.
For investor-related information, visit GoodRx’s investor relations website at GoodRx Investors.
About VIVUS
VIVUS is a biopharmaceutical company dedicated to developing and commercializing innovative therapies to address serious unmet medical needs. More information about the company can be found at VIVUS.
About QSYMIA
QSYMIA is indicated for use alongside a reduced-calorie diet and increased physical activity to assist with weight reduction and long-term weight maintenance in adults and pediatric patients aged 12 years and older who are obese, as well as in adults with overweight who have at least one weight-related comorbidity.
Important Safety Information for QSYMIA
QSYMIA should not be taken by individuals who are pregnant, planning to become pregnant, or who are allergic to its components. Serious side effects may include birth defects, severe eye problems, suicidal thoughts, and severe skin reactions. Common side effects in adults include numbness, dizziness, changes in taste, insomnia, constipation, and dry mouth.
For further details on QSYMIA, please refer to the QSYMIA Medication Guide.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements regarding anticipated consumer savings, accessibility, and the benefits of the GoodRx and Vivus partnership. These statements involve risks and uncertainties that may cause actual results to differ materially. GoodRx disclaims any obligation to update such forward-looking statements, even if subsequent events cause its views to change.